共 54 条
- [1] Fox RJ(2012)Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 1087-1097
- [2] Miller DH(2012)Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 1098-1107
- [3] Phillips JT(2015)Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate Int J MS Care 17 236-243
- [4] Gold R(2016)Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE) Int J MS Care 18 9-18
- [5] Kappos L(2019)Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study Adv Ther 36 3154-3165
- [6] Arnold DL(2019)Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes Neurol Ther 265 2980-2992
- [7] Phillips JT(2018)Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry J Neurol 40 2077-2087
- [8] Selmaj K(2018)Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study Clin Ther 86 P6.168-93
- [9] Gold R(2016)Efficacy and tolerability of fingolimod, dimethyl fumarate, and teriflunomide in patients with multiple sclerosis: real world experience from a single center Neurology 86 P3.109-119
- [10] Fox EJ(2016)Comparative efficacy and discontinuation of fingolimod and dimethyl fumarate in two large academic medical centers Neurology 3 2055217317725102-146